Benedict W F, Weissman B E, Mark C, Stanbridge E J
Cancer Res. 1984 Aug;44(8):3471-9.
The tumorigenic capacity of hybrids formed by fusion of the highly tumorigenic HT1080 human fibrosarcoma cell line with nontumorigenic normal fibroblasts was examined. The HT1080 also contains an activated N-ras oncogene. Near-tetraploid hybrids which contained an approximately complete chromosomal complement from both parental cells were nontumorigenic when 1 X 10(7) cells were injected s.c. into athymic (nude) mice, whereas the parental HT1080 cells produced tumors in 100% of the animals with no latency period following injection of 2 X 10(6) cells. Tumorigenic variants were obtained from these hybrids which had lost only a few chromosomes compared to cells from the nontumorigenic mass cultures. In addition, several near-hexaploid hybrids were obtained which contained approximately a double chromosomal complement from the HT1080 parental line and a single chromosomal complement from the normal fibroblasts. All of these near-hexaploid hybrids produce tumors in 100% of nude mice with no latency period. Our results indicate that tumorigenicity of these particular human malignant cells of mesenchymal origin can be suppressed when fused with normal diploid fibroblasts. In addition, the results suggest that tumorigenicity in this system is chromosomal dosage dependent, since a diploid chromosomal complement from normal fibroblasts is capable of suppressing the tumorigenicity of a near-diploid but not a near-tetraploid chromosomal complement from the tumorigenic HT1080 parent. Finally, the loss of chromosome 1 (the chromosome to which the N-ras oncogene has been assigned) as well as chromosome 4 was correlated with the reappearance of tumorigenicity in the rare variant populations from otherwise nontumorigenic near-tetraploid hybrid cultures. Our results also suggest the possibility that tumorigenicity in these hybrids may be a gene dosage effect involving the number of activated N-ras genes in the hybrids compared to the gene(s) controlling the suppression of the activated N-ras genes.
研究了高致瘤性的HT1080人纤维肉瘤细胞系与无致瘤性的正常成纤维细胞融合形成的杂种细胞的致瘤能力。HT1080还含有一个激活的N-ras癌基因。当将1×10⁷个细胞皮下注射到无胸腺(裸)小鼠体内时,含有来自两个亲本细胞的大致完整染色体组的近四倍体杂种细胞无致瘤性,而亲本HT1080细胞在注射2×10⁶个细胞后100%的动物中产生肿瘤且无潜伏期。从这些杂种细胞中获得了致瘤变体,与来自无致瘤性大量培养物的细胞相比,它们仅丢失了几条染色体。此外,还获得了几个近六倍体杂种细胞,其含有来自HT1080亲本系的大约两倍染色体组和来自正常成纤维细胞的单倍染色体组。所有这些近六倍体杂种细胞在100%的裸鼠中产生肿瘤且无潜伏期。我们的结果表明,这些特定的间充质来源的人恶性细胞与正常二倍体成纤维细胞融合时,其致瘤性可以被抑制。此外,结果表明该系统中的致瘤性是染色体剂量依赖性的,因为来自正常成纤维细胞的二倍体染色体组能够抑制来自致瘤性HT1080亲本的近二倍体但不能抑制近四倍体染色体组的致瘤性。最后,1号染色体(N-ras癌基因所在的染色体)以及4号染色体的丢失与原本无致瘤性的近四倍体杂种培养物中罕见变体群体中致瘤性的重新出现相关。我们的结果还提示,这些杂种细胞中的致瘤性可能是一种基因剂量效应,涉及杂种细胞中激活的N-ras基因数量与控制激活的N-ras基因抑制的基因数量的比较。